Intrexon

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Intrexon and buy or sell other stocks, ETFs, and their options commission-free!

About XON

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. 

CEO
Helen Sabzevari, PhD
CEOHelen Sabzevari, PhD
Employees
143
Employees143
Headquarters
Germantown, Maryland
HeadquartersGermantown, Maryland
Founded
1998
Founded1998
Employees
143
Employees143

XON Key Statistics

Market cap
490.03M
Market cap490.03M
Price-Earnings ratio
-2.53
Price-Earnings ratio-2.53
Dividend yield
Dividend yield
Average volume
2.74M
Average volume2.74M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$5.47
52 Week high$5.47
52 Week low
$1.11
52 Week low$1.11

Stock Snapshot

With a market cap of 490.03M, Intrexon(XON) trades at $1.39. The stock has a price-to-earnings ratio of -2.53.

On 2026-03-18, Intrexon(XON) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for Intrexon(XON) stock has reached 0, versus its average volume of 2.74M.

Over the past 52 weeks, Intrexon(XON) stock has traded between a high of $5.47 and a low of $1.11.

Over the past 52 weeks, Intrexon(XON) stock has traded between a high of $5.47 and a low of $1.11.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.